Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS

Autor:	Shuna Luo, Cai Wu, Xiaofei Xu, Dan Chen, Xingnong Ye, Jian Huang, Xiaoqiong Zhu, Jingxia Jin, Mengli Zheng, Yan Zheng
Rok vydání:	2020
Předmět:	0301 basic medicine Ruxolitinib business.industry food and beverages Decitabine Spleen Variant allele medicine.disease_cause medicine.disease 03 medical and health sciences Regimen 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Oncology hemic and lymphatic diseases 030220 oncology & carcinogenesis Cancer research Medicine Pharmacology (medical) Peripheral blood cell KRAS business Myeloproliferative neoplasm medicine.drug
Zdroj:	OncoTargets and Therapy. 13:10143-10148
ISSN:	1178-6930
Popis:	Myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) is a subtype of MDS/MPN that exhibits a combination of the features of both MDS and MPN. To date, no curative treatment is available for MDS/MPN-U; however, previous studies have suggested a potential survival advantage for ruxolitinib and hypomethylating agents. We reported a case of a JAK2-negative but KRAS-positive MDS/MPN-U patient treated with ruxolitinib plus decitabine. After treatment, the patient's clinical symptoms were moderated, and the size of the spleen and the peripheral blood cell counts were reduced. These effects might be due to the regimen's ability to reduce STAT5 activation and upregulate microRNA-181c to downregulate the variant allele frequency (VAF) of KRAS.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e6082840ea8ec769ed65e8d690bbc074 https://doi.org/10.2147/ott.s272207 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.